Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.

Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.

Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.

Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor XI (FXIa) inhibitors in a subject by administering a variant of FXIa.

Abstract: The invention relates to isolated polynucleotides, purified polypeptides, and compositions comprising pluralities of polynucleotides that are differentially expressed when foam cells are treated with oxidized low-density lipoprotein and LPS as associated with atherosclerosis. The invention also presents the use of the polynucleotides as elements on a substrate and provides methods for using the polynucleotides and polypeptides.

Abstract: The present invention relates to purified polynucleotides and compositions comprising pluralities of polynucleotides that are differentially expressed during foam cell development and are associated with atherosclerosis. The present invention presents the use of the compositions as elements on a substrate, and provides methods for using the compositions and polynucleotides.